4-chlorophenoxyacetoaldehyde dimethyl acetal | 227802-36-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-chlorophenoxyacetoaldehyde dimethyl acetal
• 英文别名: 4-Chlorophenoxyacetaldehyde dimethylacetal；1-chloro-4-(2,2-dimethoxyethoxy)benzene
• CAS: 227802-36-0
• 化学式: C₁₀H₁₃ClO₃
• 分子量: 216.664
• InChiKey: NRQPDKBGGREDNA-UHFFFAOYSA-N

物化性质

• 沸点：
  289.7±35.0 °C(Predicted)
• 密度：
  1.152±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-chlorophenoxyacetoaldehyde dimethyl acetal 在 正丁基锂 、 lithium hydroxide monohydrate 、 二乙胺基三氟化硫 、 水 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 4.5h， 生成
  参考文献：
  名称：

  [EN] GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES
  [FR] INHIBITEURS DE LA GLUCOSYLCÉRAMIDE SYNTHASE POUR LE TRAITEMENT DE MALADIES

  摘要：

  本文描述了一种I式化合物，制备这种化合物的方法，含有这种化合物的药物组合物和药物，以及使用这种化合物治疗或预防与葡萄糖酰胺合成酶（GCS）相关的疾病或症状的方法。

  公开号：

  WO2015042397A1
• 作为产物：
  描述：

  2-溴-1,1-二甲氧基乙烷 、 对氯苯酚 在 potassium carbonate 、 sodium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以2.37 g的产率得到4-chlorophenoxyacetoaldehyde dimethyl acetal
  参考文献：
  名称：

  [EN] ANTI CANCER AGENT COMPRISING AMINOACETONITRILE COMPOUND AS ACTIVE INGREDIENT
  [FR] AGENT ANTICANCÉREUX COMPRENANT UN COMPOSÉ D'AMINOACÉTONITRILE EN TANT QUE PRINCIPE ACTIF

  摘要：

  本发明涉及一种具有高安全性和优越抗癌活性的抗癌药物，该抗癌药物含有作为活性成分的氨基乙腈化合物，其化学式表示为（I），其中R1是氢原子、烷基等，R2、R3和R4相同或不同，每个是氢原子、烷基等，R5和R6相同或不同，每个是氢原子、卤原子等，m为0或1，R是卤原子、氰基、硝基、苯基（可选择地由烷基取代）等，Ar1是苯基、萘基、吡啶基、吡唑基等，每个基可选择地由卤原子、氰基、硝基、烷基等取代，W是-O-、-S-、-SO2-或-N(R7)-，其中R7是氢原子、（C1-C6）烷基等，或其药理学上可接受的盐。

  公开号：

  WO2016137010A1

文献信息

• Hypoglycemic imidazoline compounds
  申请人：ELI LILLY AND COMPANY

  公开号：EP1266897A3

  公开（公告）日：2003-12-03

  This invention relates to certain novel imidazoline compounds and analogues thereof, to their use for the treatment of diabetes, diabetic complications, metabolic disorders, or related diseases where impaired glucose disposal is present, to pharmaceutical compositions comprising them, and to processes for their preparation.The compounds have the following formula: whereinX is -O-, -S-, or -NR5-;R5 is hydrogen, C1-8 alkyl, or an amino protecting group;R4 isY is -O-, -S-, or -NR8-;Y' is -O- or -S-;

  本发明涉及某些新型的咪唑啉化合物及其类似物，以及它们用于治疗糖尿病、糖尿病并发症、代谢紊乱或相关疾病中的糖利用受损情况，涉及包含它们的药物组合物，以及它们的制备过程。这些化合物的公式如下：其中X是-O-，-S-，或-NR5-；R5是氢，C1-8烷基，或氨基保护基团；R4是Y是-O-，-S-，或-NR8-；Y'是-O-或-S-；
• [EN] CHEMICAL COMPOUNDS AS ATF4 PATHWAY INHIBITORS<br/>[FR] COMPOSÉS CHIMIQUES UTILISÉS COMME INHIBITEURS DE LA VOIE ATF4
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017212425A1

  公开（公告）日：2017-12-14

  The invention is directed to substituted piperidine derivatives. Specifically, the invention is directed to compounds according to Formula IIII: wherein A, B, X, Y, L1, L2, L3, R1, R2, R3, R4, R5, R6, R9, z2, z4, z5, and z6 are as defined herein, and salts thereof. The compounds of the invention are inhibitors of the ATF4 pathway and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, progressive supranuclear palsy, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting the ATF4 pathway and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  该发明涉及替代哌啶衍生物。具体而言，该发明涉及符合以下式III的化合物：其中A、B、X、Y、L1、L2、L3、R1、R2、R3、R4、R5、R6、R9、z2、z4、z5和z6如本文所定义，并其盐。该发明的化合物是ATF4途径的抑制剂，可用于治疗癌症、癌前综合征以及与激活的未折叠蛋白应答途径相关的疾病，如阿尔茨海默病、脊髓损伤、创伤性脑损伤、缺血性中风、中风、糖尿病、帕金森病、亨廷顿病、克雅氏病及相关朊蛋白病、进行性核上性麻痹、肌萎缩侧索硬化、心肌梗死、心血管疾病、炎症、纤维化、肝脏慢性和急性疾病、肺部慢性和急性疾病、肾脏慢性和急性疾病、慢性创伤性脑病（CTE）、神经退行性疾病、痴呆、认知障碍、动脉粥样硬化、眼部疾病、心律失常、器官移植以及器官移植运输。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制ATF4途径和治疗相关疾病的方法。
• Aminoacetonitrile derivative agricultural and horticultural insecticide containing the same and use thereof
  申请人：Nihon Nohyaku Co., Ltd.

  公开号：US06239077B1

  公开（公告）日：2001-05-29

  An aminoacetonitrile derivative of the formula (I): (wherein Ar1 and Ar2 represents phenyl group; substituted phenyl group having at least one subsituent selected from halogen atom, nitro group, cyano group, (halo) C1-C6 alkyl group, (halo) C1-C6 alkoxyl group, (substituted) pheny group, (substituted) phenyloxy group and (substituted) phenylacetylene group; (substituted) pyridyl group; and (substituted) naphthyl group, Q represents —C(R1)(R2)— (wherein R1 and R2 represent hydrogen atom, halogen atom, (halo) C1-C6 alkyl group, (halo) C1-C6 alkoxy group, (substituted) C3-C6 cycloalkyl group), or R1 and R2 may be bound to represent C2-C6 alkylene group), —CH═CH— or —C≡C—, d is 0 or an integer of 1, R3 represents hydrogen atom, (halo) C1-C6 alkyl group, R4, R5, R6, R7 and R8 represent hydrogen atom, halogen atom, (halo) C1-C6 alkyl group, W is —O—, —S—, —SO2— or —N(R9)— (wherein R9 is a hydrogen atom or C1-C6 alkyl group), and a and b are 0 or an integer of 1 to 4)), an agricultural and hortecultural insecticide containing as an active ingredient said derivative, and a method for using the insecticide.

  公式（I）的氨基乙腈衍生物：（其中Ar1和Ar2代表苯基；取代苯基至少有一个来自卤原子、硝基、氰基、（卤）C1-C6烷基、（卤）C1-C6烷氧基、（取代）苯基、（取代）苯氧基和（取代）苯基乙炔基的取代基，（取代）吡啶基；和（取代）萘基，Q代表—C（R1）（R2）—（其中R1和R2代表氢原子、卤原子、（卤）C1-C6烷基、（卤）C1-C6烷氧基、（取代）C3-C6环烷基），或R1和R2可以结合表示C2-C6烷基），—CH═CH—或—C≡C—，d为0或整数1，R3代表氢原子、（卤）C1-C6烷基，R4、R5、R6、R7和R8代表氢原子、卤原子、（卤）C1-C6烷基，W为—O—、—S—、—SO2—或—N（R9）—（其中R9为氢原子或C1-C6烷基），a和b为0或整数1至4），包含作为活性成分的所述衍生物的农业和园艺杀虫剂，以及使用该杀虫剂的方法。
• ANTICANCER AGENT COMPRISING AMINOACETONITRILE COMPOUND AS ACTIVE INGREDIENT
  申请人：NIHON NOHYAKU CO., LTD.

  公开号：US20160213640A1

  公开（公告）日：2016-07-28

  The present invention relates to an anticancer agent having a high safety and a superior anticancer activity, and an anticancer agent containing, as an active ingredient, an aminoacetonitrile compound represented by the formula (I) wherein R 1 is a hydrogen atom, an alkyl group and the like, R 2 , R 3 , and R 4 are the same or different and each is a hydrogen atom, an alkyl group and the like, R 5 and R 6 are the same or different and each is a hydrogen atom, a halogen atom and the like, m is 0 or 1, R is a halogen atom, a cyano group, a nitro group, a phenyl group optionally substituted by an alkyl group and the like, an alkyl group and the like, Ar 1 is a phenyl group, a naphthyl group, a pyridyl group, a pyrazolyl group, or the like, each of which is optionally substituted by a halogen atom, a cyano group, a nitro group, alkyl group and the like, and W is —O—, —S—, —SO 2 —, or —N(R 7 )— wherein R 7 is a hydrogen atom, a (C 1 -C 6 )alkyl group and the like, or a pharmacologically acceptable salt thereof.

  本发明涉及一种具有高安全性和优越抗癌活性的抗癌剂，以及一种含有氨基乙腈化合物作为活性成分的抗癌剂，所述氨基乙腈化合物由以下式(I)表示：其中R1为氢原子、烷基等，R2、R3和R4相同或不同，每个为氢原子、烷基等，R5和R6相同或不同，每个为氢原子、卤原子等，m为0或1，R为卤原子、氰基、硝基、苯基（可选择地由烷基取代）等，烷基等，Ar1为苯基、萘基、吡啶基、吡唑基等，每个均可选择地由卤原子、氰基、硝基、烷基等取代，W为—O—、—S—、—SO2—或—N(R7)—，其中R7为氢原子、(C1-C6)烷基等，或其药理学上可接受的盐。
• Antidiabetic pyrrolecarboxylic acids
  申请人：Pfizer Inc.

  公开号：US04511575A1

  公开（公告）日：1985-04-16

  Certain pyrrolecarboxylic and pyrroleacetic acid derivatives substituted on the pyrrole ring with thioether groups, acyl groups, phenyl, substituted phenyl, phenoxy, substituted phenoxy, benzyl or halo and optionally substituted on the pyrrole nitrogen with alkyl, and the pharmaceutically acceptable salts thereof, are useful in lowering the blood glucose levels of hyperglycemic animals.

  在吡咯环上用硫醚基团、酰基团、苯基、取代苯基、苯氧基、取代苯氧基、苄基或卤素取代的吡咯羧酸和吡咯乙酸衍生物，以及在吡咯氮上用烷基取代（可选）的药学上可接受的盐，对于降低高血糖动物的血糖水平是有用的。